Merck to Present New Data Highlighting Research Advancements Across its HIV Prevention and Treatment Pipeline at IAS 2025. Merck (NYSE: MRK), known as MSD outside of the United States and Canada ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that new data from its research ...

RAHWAY, N.J. - Pharmaceutical giant Merck (NYSE:MRK), with a market capitalization of $203 billion and impressive 77% gross profit margin, will present new data from its HIV research pipeline at ...

Merck (NYSE:MRK) recently announced updates on its HIV research, which are set to be unveiled at the upcoming International AIDS Society Conference. This announcement, coupled with the company's ...

Merck MRK announced that the FDA has accepted for review the new drug application (“NDA”) seeking approval for its investigational, once-daily, oral, two-drug, single-tablet regimen of ...

Merck Announces Positive Data from Phase 3 Trials that Show the Investigational, Once-Daily, Oral, Two-Drug Regimen of Doravirine/Islatravir (DOR/ISL) Maintained HIV-1 Viral Suppression at Week 48 ...

Merck will share updates on new scientific findings from its HIV research program, including Phase 1 results from a trial evaluating the potential for drug-drug interaction between MK-8527, the ...

Merck, known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International ...

RAHWAY, N.J.--(BUSINESS WIRE)-- Merck (), known as MSD outside of the United States and Canada, announced today that new data from its research pipeline for HIV prevention and treatment will be ...

Merck, known as MSD outside of the United States and Canada, announced that new data from its research pipeline for HIV prevention and treatment will be presented at the 13th International AIDS ...